Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required surgical intervention, such as manipulation under anesthesia, according to ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks and strokes in survivors.

This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...

ANSWER: “Floaters” are bits of cellular debris in the vitreous humor, which is the gel-filled space in between the lens and ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

A Comprehensive, Evidence-Based Review of GLP-1/GIP Agonists for Fitness and Wellness Professionals ...

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...